KRAS mutations affect up to 30% of NSCLC cases [41,126], and CNS metastases portend a worse prognosis in KRAS-mutated NSCLC patients compared to non-KRAS-mutated patients [71,127]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.